Literature DB >> 21703396

Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.

Eva Kiss1, Zoran Popovic, Jens Bedke, Shijun Wang, Mahnaz Bonrouhi, Norbert Gretz, Paula Stettner, Daniel Teupser, Joachim Thiery, Stefan Porubsky, Judith Adams, Hermann-Josef Gröne.   

Abstract

Liver X receptors (LXR)-α,β regulate intracellular cholesterol homeostasis and inhibit inflammatory gene expression. We studied the effects of the LXRα,β-agonist GW3965 on acute and chronic organ damage in the F344-LEW rat kidney transplantation model. In addition, to gain LXR isoform and cell-specific insights BALB/c kidneys were transplanted into mice with macrophage overexpression of LXRα (mLXRα-tg) and evaluated 7 and 42 days after transplantation. After 56 days GW3965 improved significantly function and morphology of rat kidney allografts by substantial reduction of mononuclear cell infiltrate and fibrosis; in vitro GW3965 reduced inflammatory activity of bone marrow-derived macrophages (BMDMs) and alloreactivity of T cells. Kidneys transplanted into mLXRα-tg mice were also protected from development of chronic allograft dysfunction. Similarly to GW3965-activated BMDMs, mLXRα-tg macrophages secreted significantly less monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β. Interestingly, 7 days after transplantation, when the total number of intragraft macrophages did not differ, evidently more arginase 1- and mannose receptor C type 1-positive cells were found in LXR rat and mice kidney allografts; in vitro both LXR activation by GW3965 and mLXRα overexpression accentuated the induction of alternative activation of BMDMs by IL-4/IL-13, suggesting an additional mechanism by LXRs to prevent graft damage. The results highlight the relevance of macrophage LXRα in allograft rejection and prevention of fibrosis.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703396      PMCID: PMC3123851          DOI: 10.1016/j.ajpath.2011.03.019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

Review 1.  The liver X receptor gene team: potential new players in atherosclerosis.

Authors:  Joyce J Repa; David J Mangelsdorf
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

Review 2.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  Chronic kidney allograft reactions in rats.

Authors:  E White; W H Hildemann; Y Mullen
Journal:  Transplantation       Date:  1969-11       Impact factor: 4.939

4.  13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy.

Authors:  Judith Adams; Eva Kiss; Ana B V Arroyo; Mahnaz Bonrouhi; Qiang Sun; Zhen Li; Norbert Gretz; Anna Schnitger; Christos C Zouboulis; Manfred Wiesel; Jürgen Wagner; Peter J Nelson; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

Review 5.  Macrophage diversity in renal injury and repair.

Authors:  Sharon D Ricardo; Harry van Goor; Allison A Eddy
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

6.  Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice.

Authors:  Daniel Teupser; Daniel Kretzschmar; Carsten Tennert; Ralph Burkhardt; Wolfgang Wilfert; Dörte Fengler; Ronald Naumann; Albrecht E Sippel; Joachim Thiery
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-11       Impact factor: 8.311

7.  Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages.

Authors:  L M Hultén; H Lindmark; U Diczfalusy; I Björkhem; M Ottosson; Y Liu; G Bondjers; O Wiklund
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

8.  The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse.

Authors:  Jeffrey W Chisholm; Jenny Hong; Scott A Mills; Richard M Lawn
Journal:  J Lipid Res       Date:  2003-08-16       Impact factor: 5.922

Review 9.  Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors.

Authors:  Cynthia Hong; Peter Tontonoz
Journal:  Curr Opin Genet Dev       Date:  2008-09-07       Impact factor: 5.578

10.  Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis.

Authors:  John T Pesce; Thirumalai R Ramalingam; Margaret M Mentink-Kane; Mark S Wilson; Karim C El Kasmi; Amber M Smith; Robert W Thompson; Allen W Cheever; Peter J Murray; Thomas A Wynn
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more
  10 in total

1.  Platelet factor 4 protects kidney allograft in a rat kidney transplantation model.

Authors:  Lei Zhang; Yichen Zhu; Dong Zhang; Jian Zhang; Ye Tian
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

2.  The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.

Authors:  T Jakobsson; L-L Vedin; T Hassan; N Venteclef; D Greco; M D'Amato; E Treuter; J-Å Gustafsson; K R Steffensen
Journal:  Mucosal Immunol       Date:  2014-05-07       Impact factor: 7.313

Review 3.  Liver X receptors in lipid metabolism: opportunities for drug discovery.

Authors:  Cynthia Hong; Peter Tontonoz
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

4.  Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.

Authors:  Michal Herman-Edelstein; Pnina Scherzer; Ana Tobar; Moshe Levi; Uzi Gafter
Journal:  J Lipid Res       Date:  2013-12-26       Impact factor: 5.922

5.  Monocytic Tissue Transglutaminase in a Rat Model for Reversible Acute Rejection and Chronic Renal Allograft Injury.

Authors:  Anna Zakrzewicz; Srebrena Atanasova; Winfried Padberg; Veronika Grau
Journal:  Mediators Inflamm       Date:  2015-04-30       Impact factor: 4.711

6.  Polarization of M2 macrophages requires Lamtor1 that integrates cytokine and amino-acid signals.

Authors:  Tetsuya Kimura; Shigeyuki Nada; Noriko Takegahara; Tatsusada Okuno; Satoshi Nojima; Sujin Kang; Daisuke Ito; Keiko Morimoto; Takashi Hosokawa; Yoshitomo Hayama; Yuichi Mitsui; Natsuki Sakurai; Hana Sarashina-Kida; Masayuki Nishide; Yohei Maeda; Hyota Takamatsu; Daisuke Okuzaki; Masaki Yamada; Masato Okada; Atsushi Kumanogoh
Journal:  Nat Commun       Date:  2016-10-12       Impact factor: 14.919

Review 7.  The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.

Authors:  Michael B Fessler
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 8.  The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis.

Authors:  Pengfei Xu; Yonggong Zhai; Jing Wang
Journal:  Int J Mol Sci       Date:  2018-04-23       Impact factor: 5.923

9.  LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.

Authors:  Katherine J Carpenter; Aurore-Cecile Valfort; Nick Steinauer; Arindam Chatterjee; Suomia Abuirqeba; Shabnam Majidi; Monideepa Sengupta; Richard J Di Paolo; Laurie P Shornick; Jinsong Zhang; Colin A Flaveny
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

10.  Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease.

Authors:  Matthew B Wright; Javier Varona Santos; Christian Kemmer; Cyrille Maugeais; Jean-Philippe Carralot; Stephan Roever; Judith Molina; G Michelle Ducasa; Alla Mitrofanova; Alexis Sloan; Anis Ahmad; Christopher Pedigo; Mengyuan Ge; Jeffrey Pressly; Laura Barisoni; Armando Mendez; Jacopo Sgrignani; Andrea Cavalli; Sandra Merscher; Marco Prunotto; Alessia Fornoni
Journal:  Nat Commun       Date:  2021-08-02       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.